Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.03
-0.02 (-0.22%)
Nov 3, 2026, 4:00 PM EST - Market closed
Telix Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Telix Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $20.54. The average 1-year stock price forecast is 127.46% higher than the current stock price, while the lowest is $17.99 (+99.22%) and the highest is $22.03 (+143.96%).
Price Target: $20.54 (+127.46%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Sep 30, 2026.
Analyst Ratings
The average analyst rating for Telix Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +121.48% | Sep 30, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 22, 2026 |
Financial Forecast
Revenue This Year
933.65M
from 803.79M
Increased by 16.16%
Revenue Next Year
1.06B
from 933.65M
Increased by 13.08%
EPS This Year
0.05
from -0.02
EPS Next Year
-0.02
from 0.05
EPS and Forward PE are based on non-GAAP adjusted numbers.